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Background and Purpose  Deciding whether or not to perform neuroimaging in primary 
headache is a dilemma for headache physicians. The aim of this study was to identify clinical 
predictors of incidental neuroimaging abnormalities in new patients with primary headache 
disorders.
Methods  This cross-sectional study was based on a prospective multicenter headache regis-
try, and it classified 1,627 consecutive first-visit headache patients according to the third edi-
tion (beta version) of the International Classification of Headache Disorders (ICHD-3β). Pri-
mary headache patients who underwent neuroimaging were finally enrolled in the analysis. 
Serious intracranial pathology was defined as serious neuroimaging abnormalities with a high 
degree of medical urgency. Univariable and multivariable logistic regression analyses were 
conducted to identify factors associated with incidental neuroimaging abnormalities.
Results  Neuroimaging abnormalities were present in 170 (18.3%) of 927 eligible patients. In 
multivariable analysis, age ≥40 years [multivariable-adjusted odds ratio (aOR)=3.37, 95% 
CI=2.07–6.83], male sex (aOR=1.61, 95% CI=1.12–2.32), and age ≥50 years at headache on-
set (aOR=1.86, 95% CI=1.24–2.78) were associated with neuroimaging abnormalities. In 
univariable analyses, age ≥40 years was the only independent variable associated with serious 
neuroimaging abnormalities (OR=3.37, 95% CI=1.17–9.66), which were found in 34 patients 
(3.6%). These associations did not change after further adjustment for neuroimaging modality.
Conclusions  Incidental neuroimaging abnormalities were common and varied in a primary 
headache diagnosis. A small proportion of the patients incidentally had serious neuroimaging 
abnormalities, and they were predicted by age ≥40 years. These findings can be used to guide the 
performing of neuroimaging in primary headache disorders.
Key Words   primary headache disorders, headache, neuroimaging, 
magnetic resonance imaging, logistic models.
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INTRODUCTION
Headache disorders are very common, with a global prevalence of 47% and a lifetime 
prevalence ≥66%.1-3 Although detailed history-taking and a neurological examination 
form the basis for an accurate diagnosis of headache disorders, neuroimaging is a critical 
tool in headache clinical practice when brain imaging facilities are available.4 However, fi-
nancial restrictions and exposure to radiation prevent routine neuroimaging being performed 
in every patient who presents with headache.5 Several guidelines discourage routine neuro-
imaging in patients with migraine or chronic headache due to a low yield found in previous 
studies.6-9 Nonetheless, the number of neuroimaging orders for evaluating headache has in-
creased in the US and other advanced countries since the publication of these guidelines.5,10-14
In real-world practice, the probability of a serious intracranial abnormality in patients 
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with headache differs widely according to the care setting 
(outpatient clinic vs. emergency department), patient char-
acteristics (e.g., age, past medical illness, and cancer history), 
and headache features (typical primary headache vs. sinister 
features suggesting secondary headache).11,15-21 Moreover, the 
development of clinical manifestations in a serious second-
ary headache are occasionally similar to that in a typical pri-
mary headache.11,19,22-25 These issues can make it difficult to 
decide whether or not to perform neuroimaging for a head-
ache disorder based only on clinical findings or simple cri-
teria in daily clinical practice.
Given the discrepancy between the guidelines and real-
world practice, identifying the predictors of intracranial ab-
normalities in specific situations might facilitate the develop-
ment of a good practical guide for decision-making regarding 
neuroimaging. Outpatient clinics are typically the most-com-
mon setting in which primary headaches are encountered.26,27 
Most neuroimaging tests can be ordered on the first visit, but 
little is presently known about the predictors of incidental in-
tracranial abnormalities in new primary headache patients. 
The aim of this study was therefore to identify the factors as-
sociated with incidental neuroimaging abnormalities in new 
patients diagnosed with primary headache disorders using 
data in a multicenter headache registry.
METHODS
Study design and patients
This cross-sectional study performed a post-hoc analysis of 
data from the HEREIN multicenter headache registry study 
[Headache Registry using the third edition (beta version) 
of the International Classification of Headache Disorders 
(ICHD-3β) for First-Visit Patients].28 This registry prospec-
tively enrolled consecutive first-visit outpatients with head-
ache at the headache clinics of 11 educational referral hos-
pitals (9 university and 2 general hospitals) across Korea (4 
in Seoul, 1 in Daejeon, 4 in Gyeonggi-do, 1 in Kangwon-do, 
and 1 in Gyeongsangnam-do) between August 2014 and Feb-
ruary 2015. The details of the HEREIN study have been re-
ported previously.29,30 
The protocol of the HEREIN study including obtaining in-
formed consent and information-use agreement forms were 
reviewed and approved by the Institutional Review Board 
(IRB) at each hospital. Each patient gave written informed 
consent before participating in the study if the need for in-
formed consent had not been waived by the IRB board at a 
particular hospital. The study protocol for this post-hoc anal-
ysis was approved by the IRB (Bundang Jesaeng General 
Hospital IRB no: 2018-12-003). The need for obtaining writ-
ten consents in this post-hoc analysis was waived by the IRB 
based on the anonymity of the data.
The eligibility criteria in the HEREIN study were as follows: 
1) headache being the chief reason for visiting the headache
clinic, 2) being Korean and aged ≥19 years, and 3) having
no disability in communication that would affect appropriate 
history-taking. The exclusion criteria were as follows: 1) hav-
ing significant communication disabilities because of im-
paired hearing, speech, or cognition, and 2) having any oth-
er serious medical or psychiatric problem identified by the
attending physician. The headache disorders were classified
by each investigator into the current headache phenotypes
using the ICHD-3β based on an evaluation that included a
structured questionnaire, clinical evaluation, and laboratory or 
neuroimaging studies as needed. The reliability of the ICHD-
3β was 0.61, indicating substantial agreement with the HERE-
IN study.30
In the analysis, the investigator selected the most-impor-
tant headache for each patient. This study enrolled patients 
who were diagnosed with a primary headache disorder and 
underwent clinical neuroimaging. The details of secondary 
headache disorders and cranial neuropathy and other facial 
pains have been reported previously.30
Assessment of neuroimaging
CT or MRI neuroimaging was performed selectively in each 
patient according to the initial clinical impressions obtained 
during history-taking and a neurological examination. Some 
patients were evaluated by CT angiography or magnetic res-
onance angiography according to the decision of the individ-
ual investigator. During the study period, patients in eight of 
the hospitals underwent 3-T MRI (Avanto, Ingenia, or Achie-
va, Philips Medical Systems, Best, the Netherlands; Verio or 
Skyra, Siemens, Erlangen, Germany) and those in the re-
maining three hospitals underwent 1.5-T MRI (Achieva or 
Intera, Philips Medical Systems; Magnetom Avanto, Siemens; 
Signa Excite, GE Healthcare, Chicago, IL, USA). The neu-
roimaging results were interpreted based on the consensus 
of two neuroradiologists in six hospitals, while one neurora-
diologist interpreted the neuroimaging results in the other 
five hospitals. The neuroimaging results were then validated 
by the researchers and used to make the final headache clas-
sification based on the ICHD-3β. 
The present analysis included patients who were diag-
nosed as having primary headaches based on the results of 
history-taking and physical and neurological examinations, 
including those who were found to have abnormal neuroim-
aging results that were not judged to be a cause of their head-
aches by the researchers. Nevertheless, if a patient had a se-
rious intracranial finding with headache potentiality and 
medical urgency, such as a primary brain tumor, clinical isch-
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emic infarct or hemorrhage, cerebral aneurysm, or cerebral 
vascular malformation, we classified them further into groups 
with and without serious neuroimaging abnormalities.
Statistical analysis
The data are present as mean±standard deviation or num-
ber (percentage) values. The study patients were first dichot-
omized into a normal group and a neuroimaging abnormalities 
group. To evaluate factors associated with serious neuroimag-
ing abnormalities, the subjects were further classified accord-
ing to whether or not they had serious neuroimaging ab-
normalities. The following clinical variables were available 
in the prospective registry: age, sex, route of referral (self-re-
ferral vs. referral by a doctor), age at headache onset, duration 
of headache, intensity of headache (severe vs. mild to mod-
erate), medication overuse, primary headache classification, 
and neuroimaging modality (MRI vs. CT). 
To define a practical age cutoff for the included patients, 
we considered the prevalence of serious and overall neuro-
imaging abnormalities according to age decades. Given re-
cently updated data on the prevalence of incidental abnormali-
ties in the general population,31 we determined the cutoff age 
as that at which the prevalence of neuroimaging was ≥10%. 
Fifty years was taken as the cutoff value for the age at head-
ache onset. We assumed that a stable history of headache can 
be inversely associated with the risk of serious neuroimag-
ing abnormalities, so we defined the cutoff value as ≥1 year. We 
measured the headache intensity using a visual analog scale 
with scores ranging from 1 to 10, and defined severe headache 
as a score of ≥7. 
Univariable logistic regression analyses were conducted to 
calculate the odds ratio (OR) and 95% confidence interval 
(CI) values for the clinical variables related to neuroimaging
abnormalities. Multivariable-adjusted logistic regression
analysis was conducted for variables that showed a signifi-
cant association in univariable analyses (p<0.05) in order to
identify independent predictors for overall and serious neu-
roimaging abnormalities. To compensate for variations accord-
ing to the selected neuroimaging modality (MRI vs. CT), we
verified the results of multivariable-adjusted logistic regres-
sion analysis by further adjusting for neuroimaging modality. 
All statistical analyses were carried out using SPSS for Win-
dows (version 18.0, SPSS Inc., Chicago, IL, USA). All reported 
probability values are two-tailed, and p<0.05 was considered
statistically significant.
RESULTS
Study patients and neuroimaging abnormalities
During the study period, 1,627 patients were prospectively 
included in the multicenter headache registry (Fig. 1). Of 
these 1,627 patients, 1,429 were diagnosed with primary 
headache disorder, and 927 eligible patients (62.6% females) 
aged 47.7±14.1 years (range, 19–85 years) were finally en-
rolled in the study for analysis. The eligible patients were older 
than the 502 patients excluded from the analysis due to no neu-
roimaging (47.7±14.1 years vs. 46.0±15.0 years, p=0.026). The 
proportions of male sex and medication overuse were higher 
for the study patients than for the excluded patients (37.4% vs. 
31.9%, p=0.036; and 6.4% years vs. 2.6%, p=0.002; respective-
ly), whereas the proportion with a headache duration ≥1 year 
was lower (33.9% vs. 41.4%, p=0.005). MRI and CT were ap-
Brain MRI: 503 patients Brain CT: 424 patients
No neuroimaging (n=502)




1,429 patients with primary 
headache disorders
Study population: 927 patients
1,627 first-visit patients with headache 
between August 2014 and Febryary 2015
Fig. 1. Flowchart showing patient enrollment in the study.
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plied to 503 (54.2%) and 424 (45.8%) patients, respectively, 
which revealed neuroimaging abnormalities in 170 patients 
(18.3%); these abnormalities were serious in 34 patients (3.6%). 
The proportions of patients with overall and serious neuro-
imaging abnormalities were 29.6% and 5.7%, respectively, in 
MRI, and 4.9% and 1.1% in CT. The most-common serious 
abnormalities were cerebral aneurysm (n=13), clinical isch-
emic infarct (n=7), and primary brain tumor (n=5) (Table 1). 
The proportions of overall and serious neuroimaging abnor-
malities increased with increasing age decade (Fig. 2). The 
cutoff value for age was predefined as ≥40 years.
Factors associated with neuroimaging abnormalities
In univariable analyses, age ≥40 years, male sex, and age ≥50 
years at headache onset were significantly associated with 
neuroimaging abnormalities (Table 2). Compared with mi-
graine as the reference, tension-type headache (TTH) was 
associated with neuroimaging abnormalities (OR=2.59, 95% 
CI=1.78–3.77). Severe headache intensity was inversely as-
sociated with neuroimaging abnormalities (OR=0.63, 95% 
CI=0.45–0.88). A headache duration ≥1 year and the pres-
ence of another primary headache disorder were marginally 
associated with neuroimaging abnormalities (OR=1.34, 95% 
CI=0.95–1.89; and OR=1.51, 95% CI=0.92–2.46; respectively); 
these associations did not reach statistical significance.
Based on the results of the univariable analyses, a multi-
variable-adjusted model was created by entering the follow-
ing potential covariates for which p<0.05 in the univariable 
analyses: age ≥40 years, male sex, age ≥50 years at headache 
onset, severe headache intensity, and TTH (Fig. 3). In con-
trast to the results of univariable analyses, severe headache 
intensity and TTH were not significantly associated with 
neuroimaging abnormalities in the multivariable-adjusted 










Clinical ischemic infarct 7 0.76
Intracerebral hemorrhage 3 0.32
Vasculitis 1 0.11
Moyamoya disease 2 0.22
Vascular malformation 3 0.32
Arnold-Chiari malformation 1 0.11
Nonserious neuroimaging abnormalities
Chronic cerebral ischemia (white-matter 
  hyperintensity or leukoaraiosis)
80 8.63
Cerebrovascular disease
Cerebral arterial stenosis 20 2.16
Subclinical ischemic infarct 7 0.76
Arachnoid cyst 3 0.32
Pineal cyst 1 0.11
Choroid fissure cyst 1 0.11
Hydrocephalus 1 0.11
Other ventricle abnormalities 1 0.11
Cerebral calcification 1 0.11
Brain atrophy 4 0.43
Encephalomalacia 2 0.22
Craniotomy not related to headache 1 0.11
Sinusitis not related to headache 24 2.59
Sinus/nasopharyngeal cyst 4 0.43
Sinus polyp 1 0.11
Mastoiditis not related to headache 2 0.22
Fig. 2. Proportions of neuroimaging abnormalities according to age 
decades.
Fig. 3. Multivariable-adjusted ORs for neuroimaging abnormalities. 
Potential variables for which p<0.05 in univariable analyses were en-
tered in multivariable-adjusted logistic regression models: age ≥40 
years, male sex, age ≥50 years at headache onset, severe headache 
intensity (VAS score ≥7), and TTH (vs. migraine). CI: confidence inter-
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model. Age ≥40 years [multivariable-adjusted odds ratio 
(aOR)=3.76, 95% CI=2.07–6.83], male sex (aOR=1.61, 95% 
CI=1.12–2.32), and age ≥50 years at headache onset (aOR= 
1.86, 95% CI=1.24–2.78) were significant predictors of neu-
roimaging abnormalities. In a multivariable analysis with fur-
ther adjustment for neuroimaging modality, age ≥40 years 
(aOR=3.37, 95% CI=1.82–6.23), male sex (aOR=1.55, 95% CI= 
1.04–2.30), and age ≥50 years at headache onset (aOR=2.14, 
95% CI=1.38–3.32) remained as significant predictors of 
neuroimaging abnormalities.
Factors associated with serious neuroimaging 
abnormalities
In univariable analyses, age ≥40 years was the only inde-
pendent variable associated with serious neuroimaging ab-
normalities (OR=3.37, 95% CI=1.17–9.66) (Table 2), with 
headache characteristics of the age at headache onset, dura-
tion of headache, severe headache intensity, and headache 
classification not being associated with serious neuroimag-
ing abnormalities. After adjusting for the neuroimaging mo-
dality, the association between age ≥40 years and serious 
neuroimaging abnormalities persisted (aOR=3.00, 95% CI= 
1.04–8.64).
DISCUSSION
This study investigated incidental neuroimaging abnormali-
ties and their predictors in new patients with primary head-
ache disorders. It was found that 18.3% of first-visit patients 
with a primary headache disorder had neuroimaging abnor-
malities, while 3.6% of these patients had serious intracrani-
al pathology despite only exhibiting the typical characteristics 
of primary headache. Among the clinical variables, except for 
the neuroimaging modality, age ≥40 years, male sex, and age 
≥50 years at headache onset were independently associated 
with neuroimaging abnormalities, while age ≥40 years was 
identified as the only predictor of serious neuroimaging ab-
normalities.
The US guideline did not draw any conclusions regarding 
the relative sensitivity of MRI and CT in migraine or non-
acute headache, which was due to a lack of available data.6 
Previous studies have produced conflicting results regarding 
the superiority of MRI over CT in detecting serious intracra-
nial pathology.32-34 Nevertheless, the recent so-called Choos-
ing Wisely campaign recommends MRI as being the gener-
ally preferred neuroimaging modality over CT in patients 
with headache disorders, except in emergency settings, con-
sidering the better diagnostic sensitivity in most circumstanc-
Table 2. Clinical characteristics and univariable ORs for neuroimaging abnormalities and serious neuroimaging abnormalities





















Age ≥40 years 491 (64.9) 155 (91.2) 5.59 (3.22–9.70) <0.001 616 (69.0) 30 (88.2) 3.37 (1.17–9.66) 0.024
Male sex 267 (35.3) 80 (47.1) 1.63 (1.16–2.28) 0.004 333 (37.3) 14 (41.2) 1.17 (0.58–2.36) 0.646
Visit route
Self-referral 465 (61.4) 112 (65.9) Reference 558 (62.5) 19 (55.9) Reference
Referred by doctor 293 (38.6) 58 (34.1) 0.82 (0.58–1.16) 0.279 335 (37.5) 15 (44.1) 1.31 (0.65–2.62) 0.437
Age ≥50 years at headache onset 224 (29.6) 97 (57.1) 3.16 (2.24–4.44) <0.001 306 (34.3) 15 (44.1) 1.51 (0.75–3.02) 0.239
Headache duration ≥1 year 247 (32.6) 67 (39.4) 1.34 (0.95–1.89) 0.092 300 (33.6) 14 (41.2) 1.38 (0.68–2.77) 0.361
Severe headache intensity,  
  VAS score ≥7
398 (52.6) 70 (41.2) 0.63 (0.45–0.88) 0.008 453 (50.7) 15 (44.1) 0.76 (0.38–1.52) 0.450
Medication overuse 46 (6.1) 13 (7.6) 1.28 (0.67–2.42) 0.449 59 (6.6) 0 (0.0) NA
Headache classification
Migraine 396 (52.3) 58 (34.1) Reference 439 (49.2) 15 (44.1) Reference
Tension-type headache 216 (28.5) 82 (48.2) 2.59 (1.78–3.77) <0.001 284 (31.8) 14 (41.2) 1.44 (0.68–3.03) 0.334
Trigeminal autonomic cephalalgias 14 (1.8) 1 (0.6) 0.48 (0.06–3.77) 0.492 15 (1.7) 0 (0.0)   0.86 (0.30–2.40)* 0.775
Other primary headache disorders 131 (17.3) 29 (17.1) 1.51 (0.92–2.46) 0.097 155 (17.4) 15 (14.7)
Data are n (%) values except where indicated otherwise.
*OR of trigeminal autonomic cephalalgias plus other primary headache disorders for significant neuroimaging abnormalities.
CI: confidence interval, NA: not applicable, OR: odds ratios, VAS: visual analog scale.
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es and the lack of radiation exposure.35,36 Our study showed 
a disparity in capturing intracranial abnormalities between 
MRI and CT: 29.6% vs. 4.9% for overall neuroimaging ab-
normalities, and 4.9% vs. 1.1% for serious intracranial ab-
normalities. These findings suggest that using MRI rather 
than CT will increase the probability of capturing both over-
all and serious neuroimaging abnormalities in patients with 
primary headache disorder, which is consistent with the neu-
roimaging recommendation made in the Choosing Wisely 
campaign.
Several similar studies have been performed since the 
guidelines were published, but they did not strictly apply the 
ICHD-3β criteria and included patients with recurrent, chron-
ic, and nonacute headaches.16,32-34 Hence, to the best of our 
knowledge, the present neuroimaging study is the first to 
have focused on a strictly defined primary headache popula-
tion. The prevalence of serious abnormalities has ranged from 
1.2% to 3.7% in previous studies, which is consistent with 
the present results.16,32-34 These findings clearly do not sup-
port performing routine neuroimaging in patients with pri-
mary or nonacute headaches. However, it seems certain that 
indiscriminately omitting neuroimaging in all patients with 
primary headache simply because they have primary head-
ache may also be impetuous and dangerous.11,19,24,34 In such 
a situation, clinicians need a more-sophisticated strategy to 
increase the probability of identifying neuroimaging abnor-
malities while reducing the routine utilization of neuroim-
aging in patients with primary headache disorders.11,21,27
This study found that patients aged ≥40 years were at risk 
of serious neuroimaging abnormalities, whereas the char-
acteristics of the headache had no association. This finding 
is somewhat consistent with a Spanish report on neuroim-
aging in patients with nonacute headaches.34 That study 
evaluated in minute detail the factors that warrant referral 
for neuroimaging according to the guidelines (i.e., the results 
of neurological examinations and sinister headache charac-
teristics such as worsening and new-onset headaches), and 
found that sinister headache characteristics were not asso-
ciated with significant neuroimaging abnormalities. While 
abnormal results in a neurological examination were identi-
fied as a strong predictor in that study, it was a predictor in 
only 29.4% of cases. The results of that study indicated that 
normal findings in a neurological examination and an unre-
markable history of headache are not sufficient conditions 
for not order neuroimaging in patients with nonacute head-
aches.19,22-24,34 It is therefore preferable for clinicians to de-
cide on neuroimaging based on their integrative judgement 
covering not only the headache characteristics and neuro-
logical examination results but also demographic charac-
teristics and the past medical history.
The US guideline has withheld a decisive judgement on 
neuroimaging in TTH.6 It is particularly interesting that, com-
pared to migraine, TTH was a predictor of neuroimaging 
abnormalities in the present univariable analysis; however, this 
association was attenuated in the multivariable models. Fur-
thermore, TTH was not associated with serious neuroimag-
ing abnormalities. It therefore remains unclear whether or 
not neuroimaging should be ordered in TTH patients. As a 
primary headache disorder, TTH may receive less attention 
and interest from both clinicians and patients because it is less 
likely to produce headache-related disability.37 However, a 
manifestation of TTH can be risky: a previous study focusing 
on headache in 111 patients with brain tumors revealed that 
77% of these patients had headaches similar to TTH.38 There-
fore, further studies should investigate neuroimaging abnor-
malities and their associated factors in patients with this fea-
tureless type of headache.25,38
This study was subject to several limitations that should be 
considered when interpreting its findings. First, it had a ret-
rospective analytic design, which meant that certain impor-
tant variables such as the results of neurological and physical 
examinations could not be included in the analysis. Further-
more, detailed information on some serious intracranial ab-
normalities such as the size and location of aneurysms, ce-
rebral infarcts, and brain tumors, and the degree of cerebral 
arterial stenosis could not be collected. Second, with regard 
to enrollment of study patients, the judgement of each indi-
vidual investigator contributed to decisions about perform-
ing neuroimaging based on clinical practice guidelines and 
patient preferences, rather than a standard protocol. This ap-
proach could have resulted in selection bias. Third, the gener-
alizability of this study is reduced by it only including study 
patients who were enrolled at secondary or tertiary referral 
hospitals. Finally, we did not classify subclinical cerebrovas-
cular disease into serious abnormalities, considering their 
low potential to induce headache and the low degree of medi-
cal urgency. However, advanced small-vessel disease, signifi-
cant intracranial atherosclerotic stenosis, or subclinical em-
bolic infarct might not be benign findings, because these 
lesions can be risk factors for future stroke, mortality, and de-
mentia.39-42 Thus, these patients might need further appro-
priate medical management in addition to caring for their 
primary headache. In this context, we need to keep in mind 
that although such neuroimaging abnormalities are harmless 
in terms of headache, they should not be ignored in order to 
ensure optimal medical care.
In conclusion, this study found that incidental neuroim-
aging abnormalities were common in new patients with pri-
mary headache disorders, whereas serious neuroimaging ab-
normalities were only found in a small proportion of them. 
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Age ≥40 years was the only independent predictor of seri-
ous neuroimaging abnormalities. These results indicate that 
neuroimaging should be selectively performed in patients with 
primary headache disorders.
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